OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Life sciences marketers contend with a flood of new data sources—and the challenge of integrating them for meaningful results
It’s common knowledge that most life sciences organizations today are getting better at managing their internal files of customer master data—the names, locations and affiliations of prescribers and other influences on therapy choices. The data is more accessible than ever, and the importance of treating internal records of this market data are better recognized. But, according to a recently published white paper from LexisNexis, the state of the art is moving ahead quickly.
And all this is happening at the very time when “no see” physicians and other restrictions on prescriber access are changing practitioners’ information needs. “They want your message, they just don’t want your messenger,” is how LexisNexis summarizes the situation.
The better-performing life sciences companies have a grasp of their internal data, including elements like these:
According to LexisNexis, though, additional external sources can add important value to prescriber and patient profiles, including such factors as:
As a vendor in this space, LexisNexis offers to bring these types of data together, as well as to cleanse, aggregate and visualize the data in forms that make it useful for business managers. LexisNexis terms this capacility “commercial agility.” LexisNexis services include:
For more information , see the white paper posted here.